Atlas Trials

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Clinical trial NCT05363722 · UNKNOWN

Trial details

NCT number
NCT05363722
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2022-05-01
Primary completion
2023-04-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.